Sudden cardiac death in heart failure with preserved ejection fraction: a target for therapy?

Heart Failure Reviews

Volumn 21, Issue 4, 2016, Pages 455-462

  Vaduganathan, Muthiah ^a   Patel, Ravi B ^a   Shah, Sanjiv J ^b   Butler, Javed ^c  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b NORTHWESTERN UNIVERSITY   (United States)

^c STONY BROOK UNIVERSITY   (United States)

Author keywords

Arrhythmias; Heart failure with preserved ejection fraction; Sudden cardiac death

Indexed keywords

ANGIOTENSIN RECEPTOR ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR;

ARTICLE; CARDIOVASCULAR MAGNETIC RESONANCE; CARDIOVASCULAR MORTALITY; COMORBIDITY; DISEASE REGISTRY; ELECTROCARDIOGRAPHY; GENE EXPRESSION PROFILING; GEOGRAPHIC DISTRIBUTION; HEART FAILURE WITH PRESERVED EJECTION FRACTION; HOSPITALIZATION; HUMAN; INCIDENCE; MOLECULAR DYNAMICS; PHENOTYPE; PREDICTION; PRESERVATION; REPOLARIZATION; SARCOPLASMIC RETICULUM; SUDDEN CARDIAC DEATH; CARDIAC RESYNCHRONIZATION THERAPY; CAUSE OF DEATH; HEART FAILURE; HEART LEFT VENTRICLE FUNCTION; HEART STROKE VOLUME; IMPLANTABLE CARDIOVERTER DEFIBRILLATOR; MORTALITY; PATHOPHYSIOLOGY; PROGNOSIS; RISK ASSESSMENT; RISK FACTOR;

CARDIAC RESYNCHRONIZATION THERAPY; CAUSE OF DEATH; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART FAILURE; HUMANS; INCIDENCE; PROGNOSIS; RISK ASSESSMENT; RISK FACTORS; STROKE VOLUME; VENTRICULAR DYSFUNCTION, LEFT;

EID: 84954314149     PISSN: 13824147     EISSN: 15737322     Source Type: Journal    
DOI: 10.1007/s10741-016-9525-z     Document Type: Article

References (57)

1. Yancy CW, Jessup M, Bozkurt B, Butler J, Casey DE Jr, Drazner MH, Fonarow GC, Geraci SA, Horwich T, Januzzi JL, Johnson MR, Kasper EK, Levy WC, Masoudi FA, McBride PE, McMurray JJ, Mitchell JE, Peterson PN, Riegel B, Sam F, Stevenson LW, Tang WH, Tsai EJ, Wilkoff BL, American College of Cardiology F, American Heart Association Task Force on Practice G (2013) 2013 ACCF/AHA guideline for the management of heart failure: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 62(16):e147–e239. doi:10.1016/j.jacc.2013.05.019
2. Deo R, Albert CM (2012) Epidemiology and genetics of sudden cardiac death. Circulation 125(4):620–637. doi:10.1161/CIRCULATIONAHA.111.023838
3. Stecker EC, Vickers C, Waltz J, Socoteanu C, John BT, Mariani R, McAnulty JH, Gunson K, Jui J, Chugh SS (2006) Population-based analysis of sudden cardiac death with and without left ventricular systolic dysfunction: two-year findings from the Oregon Sudden Unexpected Death Study. J Am Coll Cardiol 47(6):1161–1166. doi:10.1016/j.jacc.2005.11.045
4. Vaduganathan M, Michel A, Hall K, Mulligan C, Nodari S, Shah SJ, Senni M, Triggiani M, Butler J, Gheorghiade M (2015) Spectrum of epidemiological and clinical findings in patients with heart failure with preserved ejection fraction stratified by study design: a systematic review. Eur J Heart Fail. doi:10.1002/ejhf.442
5. Ambrosy AP, Fonarow GC, Butler J, Chioncel O, Greene SJ, Vaduganathan M, Nodari S, Lam CS, Sato N, Shah AN, Gheorghiade M (2014) The global health and economic burden of hospitalizations for heart failure: lessons learned from hospitalized heart failure registries. J Am Coll Cardiol 63(12):1123–1133. doi:10.1016/j.jacc.2013.11.053
6. Pitt B, Pfeffer MA, Assmann SF, Boineau R, Anand IS, Claggett B, Clausell N, Desai AS, Diaz R, Fleg JL, Gordeev I, Harty B, Heitner JF, Kenwood CT, Lewis EF, O’Meara E, Probstfield JL, Shaburishvili T, Shah SJ, Solomon SD, Sweitzer NK, Yang S, McKinlay SM, Investigators T (2014) Spironolactone for heart failure with preserved ejection fraction. N Engl J Med 370(15):1383–1392. doi:10.1056/NEJMoa1313731
7. Solomon SD, Wang D, Finn P, Skali H, Zornoff L, McMurray JJ, Swedberg K, Yusuf S, Granger CB, Michelson EL, Pocock S, Pfeffer MA (2004) Effect of candesartan on cause-specific mortality in heart failure patients: the candesartan in heart failure assessment of reduction in mortality and morbidity (CHARM) program. Circulation 110(15):2180–2183. doi:10.1161/01.CIR.0000144474.65922.AA
8. Zile MR, Gaasch WH, Anand IS, Haass M, Little WC, Miller AB, Lopez-Sendon J, Teerlink JR, White M, McMurray JJ, Komajda M, McKelvie R, Ptaszynska A, Hetzel SJ, Massie BM, Carson PE, Investigators IP (2010) Mode of death in patients with heart failure and a preserved ejection fraction: results from the irbesartan in heart failure with preserved ejection fraction study (I-Preserve) trial. Circulation 121(12):1393–1405. doi:10.1161/CIRCULATIONAHA.109.909614
9. Shah SJ, Gheorghiade M (2008) Heart failure with preserved ejection fraction: treat now by treating comorbidities. JAMA 300(4):431–433. doi:10.1001/jama.300.4.431
10. Pitt B, Gheorghiade M (2014) Geographic variation in heart failure trials: time for scepticism? Eur J Heart Fail 16(6):601–602. doi:10.1002/ejhf.112
11. Adabag S, Smith LG, Anand IS, Berger AK, Luepker RV (2012) Sudden cardiac death in heart failure patients with preserved ejection fraction. J Card Fail 18(10):749–754. doi:10.1016/j.cardfail.2012.08.357
12. Hamaguchi S, Kinugawa S, Sobirin MA, Goto D, Tsuchihashi-Makaya M, Yamada S, Yokoshiki H, Tsutsui H, Investigators J-C (2012) Mode of death in patients with heart failure and reduced vs. preserved ejection fraction: report from the registry of hospitalized heart failure patients. Circ J 76(7):1662–1669
13. Squire I (2004) Neurohormonal intervention to reduce sudden cardiac death in heart failure: what is the optimal pharmacologic strategy? Heart Fail Rev 9(4):337–345. doi:10.1007/s10741-005-7301-6 (discussion 347–351)
14. Fallavollita JA, Heavey BM, Luisi AJ Jr, Michalek SM, Baldwa S, Mashtare TL Jr, Hutson AD, Dekemp RA, Haka MS, Sajjad M, Cimato TR, Curtis AB, Cain ME, Canty JM Jr (2014) Regional myocardial sympathetic denervation predicts the risk of sudden cardiac arrest in ischemic cardiomyopathy. J Am Coll Cardiol 63(2):141–149. doi:10.1016/j.jacc.2013.07.096
15. Greenberg B (2014) Heart failure preserved ejection fraction with coronary artery disease: time for a new classification? J Am Coll Cardiol 63(25 Pt A):2828–2830. doi:10.1016/j.jacc.2014.03.033
16. Hwang SJ, Melenovsky V, Borlaug BA (2014) Implications of coronary artery disease in heart failure with preserved ejection fraction. J Am Coll Cardiol 63(25 Pt A):2817–2827. doi:10.1016/j.jacc.2014.03.034
17. Tamarappoo BK, John BT, Reinier K, Teodorescu C, Uy-Evanado A, Gunson K, Jui J, Chugh SS (2012) Vulnerable myocardial interstitium in patients with isolated left ventricular hypertrophy and sudden cardiac death: a postmortem histological evaluation. J Am Heart Assoc 1(3):e001511. doi:10.1161/JAHA.112.001511
18. Wasserstrom JA, Sharma R, Kapur S, Kelly JE, Kadish AH, Balke CW, Aistrup GL (2009) Multiple defects in intracellular calcium cycling in whole failing rat heart. Circ Heart Fail 2(3):223–232. doi:10.1161/CIRCHEARTFAILURE.108.811539
19. Shah SJ, Wasserstrom JA (2012) SERCA2a gene therapy for the prevention of sudden cardiac death: a future theranostic for heart failure? Circulation 126(17):2047–2050. doi:10.1161/CIRCULATIONAHA.112.138321
20. Shah SJ, Aistrup GL, Gupta DK, O’Toole MJ, Nahhas AF, Schuster D, Chirayil N, Bassi N, Ramakrishna S, Beussink L, Misener S, Kane B, Wang D, Randolph B, Ito A, Wu M, Akintilo L, Mongkolrattanothai T, Reddy M, Kumar M, Arora R, Ng J, Wasserstrom JA (2014) Ultrastructural and cellular basis for the development of abnormal myocardial mechanics during the transition from hypertension to heart failure. Am J Physiol Heart Circ Physiol 306(1):H88–H100. doi:10.1152/ajpheart.00642.2013
21. 2+ exchange prevents sudden death in a Guinea pig model of heart failure. Circ Res 115(1):44–54. doi:10.1161/CIRCRESAHA.115.303062
22. Sovari AA, Rutledge CA, Jeong EM, Dolmatova E, Arasu D, Liu H, Vahdani N, Gu L, Zandieh S, Xiao L, Bonini MG, Duffy HS, Dudley SC Jr (2013) Mitochondria oxidative stress, connexin43 remodeling, and sudden arrhythmic death. Circ Arrhythm Electrophysiol 6(3):623–631. doi:10.1161/CIRCEP.112.976787
23. Ferrero P, Iacovoni A, D’Elia E, Vaduganathan M, Gavazzi A, Senni M (2015) Prognostic scores in heart failure: critical appraisal and practical use. Int J Cardiol 188:1–9. doi:10.1016/j.ijcard.2015.03.154
24. Adabag S, Rector TS, Anand IS, McMurray JJ, Zile M, Komajda M, McKelvie RS, Massie B, Carson PE (2014) A prediction model for sudden cardiac death in patients with heart failure and preserved ejection fraction. Eur J Heart Fail 16(11):1175–1182. doi:10.1002/ejhf.172
25. Maurer MS, Mancini D (2014) HFpEF: is splitting into distinct phenotypes by comorbidities the pathway forward? J Am Coll Cardiol 64(6):550–552. doi:10.1016/j.jacc.2014.06.010
26. Lindman BR, Davila-Roman VG, Mann DL, McNulty S, Semigran MJ, Lewis GD, de las Fuentes L, Joseph SM, Vader J, Hernandez AF, Redfield MM (2014) Cardiovascular phenotype in HFpEF patients with or without diabetes: a RELAX trial ancillary study. J Am Coll Cardiol 64(6):541–549. doi:10.1016/j.jacc.2014.05.030
27. Dei Cas A, Khan SS, Butler J, Mentz RJ, Bonow RO, Avogaro A, Tschoepe D, Doehner W, Greene SJ, Senni M, Gheorghiade M, Fonarow GC (2015) Impact of diabetes on epidemiology, treatment, and outcomes of patients with heart failure. JACC Heart Fail 3(2):136–145. doi:10.1016/j.jchf.2014.08.004
28. D’Elia E, Vaduganathan M, Gori M, Gavazzi A, Butler J, Senni M (2015) Role of biomarkers in cardiac structure phenotyping in heart failure with preserved ejection fraction: critical appraisal and practical use. Eur J Heart Fail 17(12):1231–1239. doi:10.1002/ejhf.430
29. Ahmad T, Fiuzat M, Neely B, Neely ML, Pencina MJ, Kraus WE, Zannad F, Whellan DJ, Donahue MP, Pina IL, Adams KF, Kitzman DW, O’Connor CM, Felker GM (2014) Biomarkers of myocardial stress and fibrosis as predictors of mode of death in patients with chronic heart failure. JACC Heart Fail 2(3):260–268. doi:10.1016/j.jchf.2013.12.004
30. Zhang Y, Zhang R, An T, Huang Y, Guo X, Yin S, Wang Y, Ji S, Lv R, Zhang J, Maisel A (2015) The utility of galectin-3 for predicting cause-specific death in hospitalized patients with heart failure. J Card Fail 21(1):51–59. doi:10.1016/j.cardfail.2014.10.006
31. Whitman IR, Feldman HI, Deo R (2012) CKD and sudden cardiac death: epidemiology, mechanisms, and therapeutic approaches. J Am Soc Nephrol 23(12):1929–1939. doi:10.1681/ASN.2012010037
32. Deyell MW, Krahn AD, Goldberger JJ (2015) Sudden cardiac death risk stratification. Circ Res 116(12):1907–1918. doi:10.1161/CIRCRESAHA.116.304493
33. Singh JP, Hall WJ, McNitt S, Wang H, Daubert JP, Zareba W, Ruskin JN, Moss AJ, Investigators M-I (2005) Factors influencing appropriate firing of the implanted defibrillator for ventricular tachycardia/fibrillation: findings from the Multicenter Automatic Defibrillator Implantation Trial II (MADIT-II). J Am Coll Cardiol 46(9):1712–1720. doi:10.1016/j.jacc.2005.05.088
34. Das MK, Maskoun W, Shen C, Michael MA, Suradi H, Desai M, Subbarao R, Bhakta D (2010) Fragmented QRS on twelve-lead electrocardiogram predicts arrhythmic events in patients with ischemic and nonischemic cardiomyopathy. Heart Rhythm 7(1):74–80. doi:10.1016/j.hrthm.2009.09.065
35. Patel RB, Ng J, Reddy V, Chokshi M, Parikh K, Subacius H, Alsheikh-Ali AA, Nguyen T, Link MS, Goldberger JJ, Ilkhanoff L, Kadish AH (2010) Early repolarization associated with ventricular arrhythmias in patients with chronic coronary artery disease. Circ Arrhythm Electrophysiol 3(5):489–495. doi:10.1161/CIRCEP.109.921130
36. Simson MB, Untereker WJ, Spielman SR, Horowitz LN, Marcus NH, Falcone RA, Harken AH, Josephson ME (1983) Relation between late potentials on the body surface and directly recorded fragmented electrograms in patients with ventricular tachycardia. Am J Cardiol 51(1):105–112
37. Exner DV, Kavanagh KM, Slawnych MP, Mitchell LB, Ramadan D, Aggarwal SG, Noullett C, Van Schaik A, Mitchell RT, Shibata MA, Gulamhussein S, McMeekin J, Tymchak W, Schnell G, Gillis AM, Sheldon RS, Fick GH, Duff HJ, Investigators R (2007) Noninvasive risk assessment early after a myocardial infarction the REFINE study. J Am Coll Cardiol 50(24):2275–2284. doi:10.1016/j.jacc.2007.08.042
38. Gold MR, Ip JH, Costantini O, Poole JE, McNulty S, Mark DB, Lee KL, Bardy GH (2008) Role of microvolt T-wave alternans in assessment of arrhythmia vulnerability among patients with heart failure and systolic dysfunction: primary results from the T-wave alternans sudden cardiac death in heart failure trial substudy. Circulation 118(20):2022–2028. doi:10.1161/CIRCULATIONAHA.107.748962
39. Lund LH, Jurga J, Edner M, Benson L, Dahlstrom U, Linde C, Alehagen U (2013) Prevalence, correlates, and prognostic significance of QRS prolongation in heart failure with reduced and preserved ejection fraction. Eur Heart J 34(7):529–539. doi:10.1093/eurheartj/ehs305
40. Selvaraj S, Ilkhanoff L, Burke MA, Freed BH, Lang RM, Martinez EE, Shah SJ (2014) Association of the frontal QRS-T angle with adverse cardiac remodeling, impaired left and right ventricular function, and worse outcomes in heart failure with preserved ejection fraction. J Am Soc Echocardiogr 27(1):74–82. doi:10.1016/j.echo.2013.08.023
41. Sauer A, Wilcox JE, Andrei AC, Passman R, Goldberger JJ, Shah SJ (2012) Diastolic electromechanical coupling: association of the ECG T-peak to T-end interval with echocardiographic markers of diastolic dysfunction. Circ Arrhythm Electrophysiol 5(3):537–543. doi:10.1161/CIRCEP.111.969717
42. Sauer AJ, Selvaraj S, Aguilar FG, Martinez EE, Wilcox JE, Passman R, Goldberger JJ, Freed BH, Shah SJ (2014) Relationship between repolarization heterogeneity and abnormal myocardial mechanics. Int J Cardiol 172(1):289–291. doi:10.1016/j.ijcard.2013.12.232
43. Wilcox JE, Rosenberg J, Vallakati A, Gheorghiade M, Shah SJ (2011) Usefulness of electrocardiographic QT interval to predict left ventricular diastolic dysfunction. Am J Cardiol 108(12):1760–1766. doi:10.1016/j.amjcard.2011.07.050
44. Schelbert EB, Piehler KM, Zareba KM, Moon JC, Ugander M, Messroghli DR, Valeti US, Chang CC, Shroff SG, Diez J, Miller CA, Schmitt M, Kellman P, Butler J, Gheorghiade M, Wong TC (2015) Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J Am Heart Assoc 4(12):e002613. doi:10.1161/JAHA.115.002613
45. Iles L, Pfluger H, Lefkovits L, Butler MJ, Kistler PM, Kaye DM, Taylor AJ (2011) Myocardial fibrosis predicts appropriate device therapy in patients with implantable cardioverter-defibrillators for primary prevention of sudden cardiac death. J Am Coll Cardiol 57(7):821–828. doi:10.1016/j.jacc.2010.06.062
46. Kato S, Saito N, Kirigaya H, Gyotoku D, Iinuma N, Kusakawa Y, Iguchi K, Nakachi T, Fukui K, Futaki M, Iwasawa T, Taguri M, Kimura K, Umemura S (2015) Prognostic significance of quantitative assessment of focal myocardial fibrosis in patients with heart failure with preserved ejection fraction. Int J Cardiol 191:314–319. doi:10.1016/j.ijcard.2015.05.048
47. Schelbert EB, Wong TC, Gheorghiade M (2015) Think small and examine the constituents of left ventricular hypertrophy and heart failure: cardiomyocytes versus fibroblasts, collagen, and capillaries in the interstitium. J Am Heart Assoc 4(9):e002491. doi:10.1161/JAHA.115.002491
48. Shah SJ, Katz DH, Selvaraj S, Burke MA, Yancy CW, Gheorghiade M, Bonow RO, Huang CC, Deo RC (2015) Phenomapping for novel classification of heart failure with preserved ejection fraction. Circulation 131(3):269–279. doi:10.1161/CIRCULATIONAHA.114.010637
49. Al-Gobari M, El Khatib C, Pillon F, Gueyffier F (2013) Beta-blockers for the prevention of sudden cardiac death in heart failure patients: a meta-analysis of randomized controlled trials. BMC Cardiovasc Disord 13:52. doi:10.1186/1471-2261-13-52
50. Pitt B, Gheorghiade M, Zannad F, Anderson JL, van Veldhuisen DJ, Parkhomenko A, Corbalan R, Klug EQ, Mukherjee R, Solomon H, Investigators E (2006) Evaluation of eplerenone in the subgroup of EPHESUS patients with baseline left ventricular ejection fraction ≤ 30%. Eur J Heart Fail 8(3):295–301. doi:10.1016/j.ejheart.2005.11.008
51. Pitt B, White H, Nicolau J, Martinez F, Gheorghiade M, Aschermann M, van Veldhuisen DJ, Zannad F, Krum H, Mukherjee R, Vincent J, Investigators E (2005) Eplerenone reduces mortality 30 days after randomization following acute myocardial infarction in patients with left ventricular systolic dysfunction and heart failure. J Am Coll Cardiol 46(3):425–431. doi:10.1016/j.jacc.2005.04.038
52. Desai AS, McMurray JJ, Packer M, Swedberg K, Rouleau JL, Chen F, Gong J, Rizkala AR, Brahimi A, Claggett B, Finn PV, Hartley LH, Liu J, Lefkowitz M, Shi V, Zile MR, Solomon SD (2015) Effect of the angiotensin-receptor-neprilysin inhibitor LCZ696 compared with enalapril on mode of death in heart failure patients. Eur Heart J 36(30):1990–1997. doi:10.1093/eurheartj/ehv186
53. Fishman GI, Chugh SS, Dimarco JP, Albert CM, Anderson ME, Bonow RO, Buxton AE, Chen PS, Estes M, Jouven X, Kwong R, Lathrop DA, Mascette AM, Nerbonne JM, O’Rourke B, Page RL, Roden DM, Rosenbaum DS, Sotoodehnia N, Trayanova NA, Zheng ZJ (2010) Sudden cardiac death prediction and prevention: report from a National Heart, Lung, and Blood Institute and Heart Rhythm Society Workshop. Circulation 122(22):2335–2348. doi:10.1161/CIRCULATIONAHA.110.976092
54. Every NR, Parsons L, Hlatky MA, McDonald KM, Thom D, Hallstrom AP, Martin JS, Weaver WD (1997) Use and accuracy of state death certificates for classification of sudden cardiac deaths in high-risk populations. Am Heart J 134(6):1129–1132
55. Iribarren C, Crow RS, Hannan PJ, Jacobs DR Jr, Luepker RV (1998) Validation of death certificate diagnosis of out-of-hospital sudden cardiac death. Am J Cardiol 82(1):50–53
56. Greene SJ, Gheorghiade M (2014) Matching mechanism of death with mechanism of action: considerations for drug development for hospitalized heart failure. J Am Coll Cardiol 64(15):1599–1601. doi:10.1016/j.jacc.2014.06.1199
57. Chan MM, Lam CS (2013) How do patients with heart failure with preserved ejection fraction die? Eur J Heart Fail 15(6):604–613. doi:10.1093/eurjhf/hft062